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Background Epigenetic events, including histone acetylation modifications, have 
been demonstrated to have critical roles in the therapeutic outcome of Tumor 
Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL) application in 
eliminating malignant tumors. Histone acetyl transferase and deacetylase (HDAC 
and HAT) enzymes are known to play the central role in the process of histone 
acetylation modification. In the present study, we investigated the potential 
application of a combining novel HDAC or HAT inhibitors with TRAIL variants in 
killing human carcinoma cells.  
Methods A panel of different carcinoma cell lines (colon, lung and hepatocellular 
carcinoma) was treated with different TRAIL variants in presence of different 
HDAC or HAT inhibitors to evaluate its effect on the viability of these cell lines. 
Result In vitro treatment of human carcinoma cells with different receptor specific 
and wt TRAIL variants induced a reduction in viability with DR4 specific TRAIL 
being the most efficient. However, a significant impairment in cell viability was 
observed during administration of TRAIL in presence of HDAC inhibitor SAHA or 
HAT inhibitor C646.  
Conclusion Here, we present evidence for the successful application of the receptor 
specific TRAIL variants in the elimination of human carcinoma cells via 
simultaneous inhibition HAT or HDAC enzymes. The combined HAT or HDAC 
inhibitor and TRAIL variant regimen may thus represent a new therapeutic 
compound against different human carcinoma.  
 





Since TRAIL protein has been introduced to the field of tumor therapy it has raised 
many hopes for specific elimination of tumor cells. The application of TRAIL to 
induce apoptosis in tumors is mainly grounded on up-regulation of TRAIL receptors 
in tumor cells versus normal cells. TRAIL has two dedicated receptors (DR5 and 
DR4) that signal apoptosis via binding to TRAIL agonists. However, up-regulation 
of decoy receptors (DCR1 and DCR2) in tumor cells could lead to abortive signaling 
and impaired apoptosis. This later is considered the primary source of TRAIL 
resistance and tumor evasion. To address this problem receptor specific agonist 
TRAIL has already been introduced both in the form of type specific mutant TRAIL 
agonists or monoclonal antibody against specific TRAIL receptors DR4 and DR5 
[1][2][3]. Dynamic of wild type (wt) occurring TRAIL and mutant TRAIL 
interaction with their receptors have already been well characterized[4]. Receptor 
specific agonists could reduce the decoy receptor-mediated antagonism, hence a 
cumulative effect by using receptor specific TRAIL is lowering required 
administrated dose with possibly fewer side effects that attached to TRAIL adverse 
effect [4][5]. Epigenetic alterations could also lead to defective apoptotic signaling 
and develop TRAIL resistance in tumor cells. Histone acetylation is the result of the 
balance between the activity of histone deacetylases (HDAC) and histone acetyl 
transferases (HAT). Extent of histone acetylation determines the extent of chromatin 
relaxation hence plays a major role in the regulation of gene expression. 
Deregulation of HAT or HDAC in tumor cells is associated with the failure to 
undergo apoptosis in cancer cells.  Through chromatin condensation HDAC could 





repress the expression of tumor suppressor and pro-apoptotic genes and confer 
resistance to apoptosis [6][7][8] , whereas HATs affect the chromatin remodeling 
and can promote expression of cancer related proto-oncogenes in cancer[9][10][11]. 
Extensive studies have demonstrated synergistic effects of HDAC inhibitors and 
TRAIL on apoptosis [6][7][8]. Unlike HDAC inhibitors, the interactive role of HAT 
inhibitors and TRAIL on apoptosis have been less characterized. In this study we 
investigate the potential application of TRAIL variants in combination with HDAC 
and HAT inhibitors to eliminate cancer cells. 
 
Methods and materials 
Cells and cultures 
 SW948 [SW-948] (ATCC CCL-237) Dukes' type C, grade III, colorectal 
adenocarcinoma, was cultured in Leibovitz's L-15 Medium (Sigma-Aldrich) 
supplemented with 10% Fetal calf serum. NCI-H460 [H460] (ATCC HTB-177) 
Human lung carcinoma cell line cultured in RPMI-1640 (Sigma-Aldrich) Medium 
supplemented with 10 % fetal calf serum. HepG2 [HEPG2] (ATCC HB-8065) 
hepatocellular carcinoma cell line cultured in DMEM high glutamine (Glutamax) 
(Sigma-Aldrich) supplemented with 10 % fetal calf serum. Huh-7 cell line cultured 
in DMEM high glutamine (Glutamax) (Sigma-Aldrich) supplemented with 10 % 
fetal calf serum. All the cells were grown in 37°C in presence of 5 % Co2.  
Chemicals 
Receptor specific or wild type TRAIL were produced and purified from prokaryotic 
expression as previously described [1][2][3]. Crystal violet solution (Sigma-




Aldrich), HAT inhibitors C646 Ca t# S7152 and MG149 cat # S7476 (Selleckchem). 
HDAC inhibitors; SAHA N-hydroxy-N′-phenyl-octanediamide, Suberoylanilide 
hydroxamic acid, Vorinostat, cat #SML0061 and MS-275 A HDAC1 and HDAC3 
inhibitor Synonym: 3-pyridinylmethyl[[4-[[(2-aminophenyl) amino] carbonyl] 
phenyl] methyl] carbamate, MS-275 (Entinostat, SNDX-275), N-(2-Aminophenyl) -
4- [N -( pyridine-3 etylmethoxycarbonyl ) naminomethyl] benzamide cat # EPS002 
(Sigma-Aldrich).  
Crystal violet viability assay 
 Then, 100 µl of a cell suspension 10 4 cells/ml for mentioned cells were gently 
introduced into each well from 96 well plates. After being kept undisturbed at room 
temperature for 20 min to allow the cells to sediment, the plates were transferred to a 
CO2 incubator and cultured for 2 days. The cells then were treated with 100 µl of 
medium containing different combination of wt and receptor specific TRAIL in 
presence or absence of HAT or HDAC inhibitors for hours. For cell fixation each 
well received 50 ul glutaraldehyde (25 %) and was left for at least 20 min. After 
being washed with water, the plates were stained with 0.4 % crystal violet solution 
in methanol for 30 min. Absorbance at 590 nm was measured by an automatic 
microtiter plate reader. Average absorbance of the control wells, which received no 










HAT and HAC inhibitors markedly potentiate TRAIL lethality in colon 
carcinoma cell line 
To evaluate the effect of receptor specific TRAIL, different amounts from receptor 
specific or wt TRAILs were added to SW948 cells and the viability of cells was 
determined 24 hours later by the CVS assay. SW948 cells showed slight decrease in 
viability occurred in the presence of different TRAIL variants at sub-lethal 
concentration. Also comparison between different concentrations of SAHA and 
Entinostat showed SAHA displays a greater potential in reducing viability of SW948 
cells (Fig 1). Co-treatment of SW948 cells with different type of TRAIL and 
HADAC inhibitors significantly increased SW948 sensitivity to apoptosis (70 % and 
90 % in order for Entinostat and HDAC) at the sub-lethal concentration (10ng/ml) of 
TRAIL variants (Fig. 1). We next evaluated the contribution of HAT inhibitors with 
respect to their effect on increasing SW948 cells sensitivity towards TRAIL 
variants. Measurement of viability in SW948 cells treated with TRAIL variants 
(10ng/ml) in presence of MIG 149 and C646 showed a decrease of 40 % and 80 % 
respectively in compare with cells treated only with TRAIL variants (Fig. 2).  
Potentiation of apoptosis in H460 lung carcinoma exposed to TRAIL and 
HAT/HDAC inhibitors  
 To further investigate the apoptosis-inducing activities of different TRAIL variants, 
H460 lung carcinoma cells were incubated with PBS or the aforementioned TRAIL 
variants proteins. Consistent with cell viability results, only DR4 specific TRAIL 
induced robust apoptosis of H460 cells (90 %), whereas wt and DR5 specific TRAIL 




were less effective in reducing viability at lower concentration of 10 ng/µl (Fig. 3). 
In marked contrast to results obtained following exclusive treatment of cells with 
HDAC inhibitor drugs, simultaneous exposure of cells to a sub-toxic concentration 
of TRAIL (10 ng/ml) in conjunction with 1uM Entinostat or SAHA resulted in a 
very dramatic decrease in cell survival (Fig. 3).  To determine whether activators of 
the extrinsic pathway could similarly enhance HAT inhibitor-associated lethality, 
H460 cells were simultaneously exposed to either C646 or MG149 in combination 
with different TRAIL variants. As shown in Fig. 4, while DR5 receptor specific 
TRAIL alone was minimally toxic, co-administration of HAT inhibitors and in 
particular C646 resulted in marked increase in the extent of cell survival loss. The 
maximum cytotoxic effect was achieved by combining 10 uM C646 and TRAIL (10 
ng/ml) (Fig .4).  
Co-administration of TRAIL with HDAC inhibitors potently induces apoptosis 
in human hepatocellular carcinoma cell lines   
To determine whether the previous findings were restricted to colon or lung 
carcinoma cells, parallel studies were performed using human hepatocellular 
carcinoma cell line;  Huh-7. Cells were exposed for 24 h to 1 or 5 -mM Entinostat or 
SAHA in presence of 10ng or 100-ng/ml TRAIL variants after which cell death was 
assayed. Responses to HDAC inhibitors given individually varied between the 
administered drugs with Huh-7 cells showed greater sensitivity to SAHA in compare 
to Entinostat. Simultaneous exposure of cells to TRAIL in conjunction with HDAC 
inhibitors resulted in a clear increase in apoptosis, comparable with results obtained 
in cells only treated with SAHA. This effect however was most pronounced for DR4 





TRAIL ligand treated cells (Fig. 5). In the same way administration of HAT 
inhibitors showed that Huh-7 cells showed greater sensitivity to C646 in compare 
with MG149. Co-administration of C646 and DR4 TRAIL promises to be the most 
effective combination in inducing apoptosis in Huh-7 cells (Fig. 6). 
 
Conclusion 
TRAIL agonists are vastly used to kill malignant cells that express TRAIL receptors. 
The extrinsic pathway of apoptosis is initiated by the binding of death receptors, 
including Fas (CD59), TNF receptor-1 (TNFR-1) and TRAIL receptors (DR-4 and -
5) to their correspondent ligands and the subsequent activation of caspase-8 and 
caspase-10[12]. However, usefulness of TRAIL in inducing apoptosis could be 
hampered by the resistance of some cancer cells to TRAIL. Of all known 
mechanism of TRAIL resistance epigenetic events, including histone acetylation 
modifications, have been demonstrated to have critical roles in developing resistance 
toward TRAIL through different mechanisms.  
The present findings indicate that simultaneous administration of TRAIL with 
HDAC inhibitors induces apoptosis through sensitization of malignant cells to 
TRAIL effect. Treatment a panel of carcinoma cell lines (Lung, colon and 
hepatocellular) with TRAIL variants in presence of SAHA drastically enhance cells 
sensitivity to apoptosis. In contrast, application of Entinostat did not significantly 
increase TRAIL sensitivity. Importantly the results emphasize SAHA sensitization 
of TRAIL-resistant cells achieved with the lowest concentration of SAHA and 




TRAIL that otherwise were not effective alone.  However, the main question 
remains as to how combined treatment with SAHA and TRAIL resulted in such a 
significant impairment in cell survival. In fact the cooperative effects of SAHA and 
TRAIL could be interpreted in several levels; HDAC inhibitors  can upregulate the 
expression of death receptors and their ligands in transformed cells, yet not in 
normal cells [13][14]. TRAIL receptors DR-4 and DR-5 were induced both in vivo 
[14][15]  and in vitro  [16] by different types of HDAC 
inhibitors[17][18][19][20][21]. On the basis of our results, receptor specificity of 
TRAIL variants did not significantly contribute to their killing effect in presence of 
SAHA. This later could indicate HDAC inhibitors mechanism of action in 
sensitizing cells is independent of a specific TRAIL receptor up-regulation. HDAC 
inhibitors could also amplify TRAIL killing effect in cancer cells through other 
mechanisms including; up-regulation of caspase-8, down-regulation of anti-
apoptotic molecules like  cFLIP  and Bcl-2 proteins (e.g., Bcl-2, Bcl-XL, and Mcl-
1), increase in pro-apoptotic Bcl-2 proteins (e.g., Bid, Bim, and Bax), and re-
distribution of TRAIL receptors in lipid rafts on the surface of targeted cells 
[22][23][24] . However, the exact mechanism of this phenomenon needs to be 
further investigated. Unlike HDAC inhibitors, less extensive studies have been 
carried out to unravel the role of HAT inhibitors in TRAIL-induced apoptosis. 
Selective inhibition of HAT inhibits the DNA damage response in malignant cell 
lines [11]. Here we evaluate cytotoxicity induced by pretreatment of multiple 
myeloma cells with C646 or MG149 followed by TRAIL using CVS cell 
proliferation assay. Whereas MG149, low concentration of C646 (HAT inhibitor) 





augments TRAIL-induced Cytotoxicity in multiple carcinoma cell lines. Indirect 
evidence suggests some level of regulation on TRAIL receptor expression due to 
effect of HAT inhibitors. For instance P53 a key factor that increases  as a result of 
inhibiting  P300/BCP (histone acetyltransferase) could upregulate DR5 receptor in 
conjunction with NF-κB[15][25][26][27]. Selective inhibition of P300 HAT via 
C646 HAT inhibitor could also decrease expression of a series of genes including 
Ubiquitin-like with PHD and ring finger domains (UHRF1) (responsible for G1/S 
transition and p53-dependent DNA damage checkpoint), DEP domain containing 
(DEPDC1) (responsible for inhibition of apoptosis) up to 14 times; while increasing 
the expression of P53 gene that is responsible for response to diverse cellular 
stresses and apoptosis senescence 1.2 times [28][29][30]. In conclusion, present 
evidence indicates that TRAIL in conjunction with HDAC or HAT inhibitors 
constitutes a potent apoptotic stimulus in human carcinoma cells. Previous studies 
have demonstrated that co-administration of HDAC inhibitor with TRAIL enhance 
the antitumor activity of TRAIL [6][7][8]. The present results suggest that similar 
interactions occur in human carcinoma cells exposed to TRAIL in combination with 
HAT inhibitors. Given that there is a growing interest in combined regimen for more 
efficient application of TRAIL in anti-tumor therapy, the current finding is the first 
to show a significant anti-tumor concept of combining TRAIL variants with HAT 
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Figure 1: Simultaneous application of histone deacetylase inhibitor and TRAIL enhances the efficiency of TRAIL 
variants in SW948 colon carcinoma cell line. 























Figure 2: Simultaneous application of HAT inhibitor and TRAIL enhance the efficiency of TRAIL variants in SW948 
colon carcinoma cell line. 
 



























Figure 3: Simultaneous application of histone deacetylase inhibitor and TRAIL enhance the efficiency of TRAIL variants in 
H460 (lung carcinoma) cell line. 




























Figure 4: Simultaneous application of histone acetylase inhibitor and TRAIL enhance the efficiency of TRAIL variants in 
H460 cell line. 




























Figure 5: Simultaneous application of histone deacetylase inhibitor and TRAIL enhance the efficiency of TRAIL variants in 
Huh-7 (hepatocellular carcinoma) cell line. 




























Figure 6: Simultaneous application of histone acetylase inhibitor and TRAIL enhance the efficiency of TRAIL variants in Huh-7 cell 
line. 
